DDInter458 DDInter741
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPB1
HSPB1 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine {u} (Compound) upregulates {v} (Gene) UFM1
UFM1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) downregulates HSPB1 (Gene) and HSPB1 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cyclosporine (Compound) upregulates UFM1 (Gene) and UFM1 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin